Pliant director granted 70,000 stock options

Pliant Therapeutics director Thomas A. McCourt received a grant of stock options covering 70,000 shares of common stock.

Rhea-AI Filing Summary

Pliant Therapeutics director Thomas A. McCourt received a grant of stock options covering 70,000 shares of common stock. The options have an exercise price of $1.14 per share and expire on June 11, 2036.

These options were granted as compensation and do not represent an open-market purchase. According to the vesting schedule, 25% of the options vest on each of October 1, 2026, January 1, 2027, and April 1, 2027, with the remaining 25% vesting on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, subject to McCourt’s continued service on the board.

Insider Trade Summary

Grant/Award: 70,000 shares

Grant/Award 1 txn

Insider MCCOURT Thomas A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	70,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 70,000 contracts (Direct)

Footnotes (1)

1. F1. 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

Key Figures

Options granted: 70,000 options Exercise price: $1.14 per share Post-grant derivative holdings: 70,000 options +4 more

7 metrics

Options granted 70,000 options Stock option grant to director Thomas A. McCourt

Exercise price $1.14 per share Exercise price of newly granted options

Post-grant derivative holdings 70,000 options Total derivative securities following transaction

Expiration date June 11, 2036 Option expiration

First vesting date October 1, 2026 25% of options vest

Second vesting date January 1, 2027 Additional 25% of options vest

Third vesting date April 1, 2027 Additional 25% of options vest

Key Terms

Stock Option (Right to Buy), exercise price, vest and become exercisable, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 1.1400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"25% of the shares subject to such option vest and become exercisable"

annual meeting of stockholders financial

"the next annual meeting of stockholders, subject to the Reporting Person's continued service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PLIANT THERAPEUTICS (PLRX) report for Thomas A. McCourt?

PLIANT THERAPEUTICS reported a grant of stock options to director Thomas A. McCourt covering 70,000 shares of common stock. The options are a compensation award rather than an open-market purchase and give the right to buy shares at a fixed exercise price.

What is the exercise price and size of the new PLRX stock option grant?

The stock option grant to director Thomas A. McCourt covers 70,000 shares of PLIANT THERAPEUTICS common stock. The options carry an exercise price of $1.14 per share, meaning that is the price he must pay to purchase shares when options are exercised.

How do the new PLRX options granted to Thomas A. McCourt vest over time?

The 70,000-share option grant vests in four 25% segments. Three tranches vest on October 1, 2026, January 1, 2027, and April 1, 2027. The final 25% vests on the earlier of the June 11, 2027 grant anniversary or the next annual stockholder meeting.

When do Thomas A. McCourt’s newly granted PLRX stock options expire?

The newly granted stock options to director Thomas A. McCourt expire on June 11, 2036. After that expiration date, any unexercised options will no longer be usable, so the long-dated term provides a multi-year window in which he can choose to exercise.

Is the PLRX Form 4 transaction an open-market buy or a compensation award?

The reported Form 4 transaction is a compensation-related award, not an open-market share purchase. It reflects a grant of stock options with a $1.14 exercise price, giving Thomas A. McCourt the right to buy 70,000 shares subject to the vesting schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 05:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCCOURT Thomas A

(Last) (First) (Middle)

C/O PLIANT THERAPEUTICS, INC.

331 OYSTER POINT BOULEVARD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PLIANT THERAPEUTICS, INC. [ PLRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.14	06/11/2026		A		70,000		(1)	06/11/2036	Common Stock	70,000	$0	70,000	D

Explanation of Responses:

1. 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

Remarks:

	/s/ Jennifer Woo, attorney-in-fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)